GUBBA PHARMA IN E NEWS

Read More

Hospitals to get gold, silver, bronze ratings based on quality of facilities

September 25, 2019 Gubba Pharma In E News

The new system will be based on self-assessment and would be evidence-based. Once the self assessment is done, there will be a desktop assessment done...

Continue Reading

Read More

New way to test for drug resistant infections

September 18, 2019 Gubba Pharma In E News

Scientists have developed a method to test whether an infection is resistant to common antibiotics. Beta-lactam antibiotics (such as penicillin) are one of the most...

Continue Reading

Read More

Natco Pharma lines up 20 `Para IV’ products

September 18, 2019 Gubba Pharma In E News

Para IV products mean, “the first company which submits a completed ANDA (Abbreviated New Drug Application) is given marketing exclusivity for 180 days.” Natco Pharma...

Continue Reading

Read More

India joins Global Antimicrobial Resistance Research and Development Hub

September 18, 2019 Gubba Pharma In E News

India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This will expand the global partnership working to...

Continue Reading

Read More

Hyderabad will be medical devices hub soon: KTR

September 11, 2019 Gubba Pharma In E News

TRS working president KT Rama Rao on Saturday welcomed Surat-based medical devices manufacturer Sahajanand Medical Technologies (SMT), which is a leading manufacturer of coronary stents,...

Continue Reading

Read More

Glenmark Pharma gets USFDA nod for skin treatment ointment

September 11, 2019 Gubba Pharma In E News

Glenmark Pharmaceuticals has received final approval from the US health regulator for Pimecrolimus Cream, used to treat skin conditions such as eczema. The approved product...

Continue Reading

Read More

Alembic Pharmaceuticals gets USFDA nod for ophthalmic solution

September 11, 2019 Gubba Pharma In E News

The approved product is therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, 0.09 percent, of Bausch & Lomb. Drug firm Alembic Pharmaceuticals...

Continue Reading

Read More

FDA approves Keytruda as treatment for specific type of esophageal cancer

August 28, 2019 Gubba Pharma In E News

The U.S. Food and Drug Administration (FDA) has approved a new treatment option for patients with advanced esophageal cancer — the immunotherapy drug pembrolizumab, known...

Continue Reading

Read More

DSV-Panalpina merger creates world’s second largest airfreight forwarder

August 28, 2019 Gubba Pharma In E News

DSV has announced that its acquisition of Panalpina will finally be completed in a deal worth $5.5bn. The combined company will be recognised as DSV...

Continue Reading